Switzerland-based Novartis has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for crizanlizumab (SEG101) in order to prevent vaso-occlusive crises in patients of all genotypes with sickle cell disease, it was reported yesterday.
The product is a humanised anti-P-selectin monoclonal antibody being studied to restrict vaso-occlusive crises in sickle cell disease.
The status has been offered based on positive data from the phase II Sustain study, which compared the P-selectin inhibitor crizanlizumab against placebo in patients with sickle cell disease. The study indicated that crizanlizumab decreased the median annual rate of vaso-occlusive crises leading to health care visits by 45.3% compared to placebo in patients with or without hydroxyurea therapy, according to the company. The sustain study also showed that crizanlizumab significantly increased the percentage of patients who did not experience any vaso-occlusive crises against placebo during treatment.
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection